Claritev (CTEV) Panoramica del titolo
Claritev Corporation, insieme alle sue consociate, fornisce soluzioni di analisi dei dati e di tecnologia end-to-end per la gestione dei costi, dei pagamenti e dell'integrità dei ricavi al settore sanitario negli Stati Uniti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 0/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 0/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
CTEV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Claritev Corporation
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$21.24 |
| Massimo di 52 settimane | US$74.07 |
| Minimo di 52 settimane | US$11.50 |
| Beta | 0.77 |
| Variazione di 1 mese | -5.39% |
| Variazione a 3 mesi | -8.88% |
| Variazione di 1 anno | -26.20% |
| Variazione a 3 anni | -58.52% |
| Variazione a 5 anni | -93.55% |
| Variazione dall'IPO | -94.54% |
Notizie e aggiornamenti recenti
Recent updates
Aggiornamento della narrazione • May 05
CTEV: Volume Resilience And 2026 Buybacks Will Support Future Upside
Claritev's analyst fair value has been revised from $42.75 to $39.80 as analysts factor in slightly lower profit margin assumptions and a small reset in future P/E expectations, in line with recent price target trims from several firms following updated guidance and investment plans. Analyst Commentary Street research on Claritev has shifted toward more conservative assumptions on margin, revenue mix and investment timing, while still highlighting areas where execution could support the current valuation over time.Seeking Alpha • Apr 20
Claritev: Compounding Debt Meets Legacy Business Stabilization (Rating Upgrade)
Summary Claritev is upgraded to 'Hold' after a 32% decline, with the short thesis largely played out. Legacy business revenues are stabilizing, showing 6.2% YoY Q4 growth and accelerating full-year growth, despite margin pressure from regulatory changes. BenInsights' failed pivot is now fully reflected in CTEV’s valuation; any positive developments could act as catalysts. CTEV’s $4.6B debt load and negligible free cash flow keep valuation unattractive, with a 9.2x EV/EBITDA multiple deemed expensive for its risk profile. Read the full article on Seeking AlphaAggiornamento della narrazione • Apr 20
CTEV: Entrenched Payer Role And 2026 Buyback Capacity Will Support Upside
Claritev's analyst price target has been reset lower, with the model's fair value estimate moving from $44.75 to $42.75 as analysts factor in reduced formal targets from Citi, Guggenheim, and Wells Fargo, along with updated views on revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent Street research on Claritev has coalesced around lower price targets, but the tone is mixed, with analysts highlighting both upside drivers and areas where execution and guidance keep them cautious.
Aggiornamento della narrazione • Apr 05
CTEV: Entrenched Position And Buybacks Will Support Volume Driven Earnings Power
Analysts cut the Claritev price target to $21, with updated models reflecting slightly different revenue growth, profit margin, and future P/E assumptions following recent guidance and sector research. Analyst Commentary Recent Street research on Claritev points to a reset in expectations, with several bearish analysts cutting price targets and highlighting execution and balance sheet risks, even as ratings in the sample remain unchanged.Aggiornamento della narrazione • Mar 22
CTEV: Entrenched Position And Buybacks Will Support More Sustainable Future Margins
Analysts have reduced the Claritev price target to $21 from $33, reflecting updated expectations for slower revenue growth, slightly lower profit margins, and a lower future P/E multiple, even as they cite solid recent results and continued investment in growth initiatives. Analyst Commentary Recent research updates show a clear reset in expectations for Claritev, with multiple firms cutting price targets while generally maintaining existing ratings.Aggiornamento della narrazione • Mar 07
CTEV: Entrenched Payer Role And 2026 Guidance Reset Will Support Upside
The analyst price target for Claritev has been reduced from $57.25 to $44.75. Analysts cited lower revenue growth and profit margin assumptions, as well as a revised future P/E expectation following recent price target cuts from multiple firms.Aggiornamento della narrazione • Feb 21
CTEV: Entrenched Position And Deleveraging Will Support More Sustainable Future Margins
Claritev's analyst price target has been reset lower to $63, down from $80, as analysts factor in a slightly lower future P/E assumption of 9.87x. They also note that the company remains an entrenched vendor with accelerating revenue but elevated leverage that can weigh on valuation.Aggiornamento della narrazione • Feb 06
CTEV: Entrenched Payer Position And Deleveraging Will Support Future Upside
Analysts have trimmed their fair value estimate for Claritev to $57.25 from $85, citing updated Street price targets in the $33 to $63 range and reduced future P/E assumptions, while also acknowledging steady revenue growth and margin expectations. Analyst Commentary Bullish and cautious views on Claritev are both in play, and that split is driving a wide range of price targets and valuation opinions.Aggiornamento della narrazione • Jan 23
CTEV: Revenue Recovery And Deleveraging Will Support More Sustainable Future Margins
Narrative Update Opening Analysts have trimmed their fair value estimate for Claritev from $80 to $33, citing a lower Street price target that ranges from $63 at the high end to $33, and a view that stronger revenue growth and steady margins are now balanced by a less premium future P/E and concerns about elevated leverage. Analyst Commentary Recent research updates on Claritev highlight a split view, with some firms still constructive on the long term while taking down price targets and others starting coverage at more neutral levels.Articolo di analisi • Jan 18
Claritev Corporation (NYSE:CTEV) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the Claritev Corporation ( NYSE:CTEV ) share price has dived 26% in the last...Aggiornamento della narrazione • Jan 09
CTEV: Best In Class Margins And Deleveraging Efforts Will Support Upside
Analysts have raised their average price target on Claritev to US$74 from US$55, citing confidence in the company's ability to accelerate growth while maintaining strong margins, even as some remain cautious about leverage and valuation. Analyst Commentary Recent research paints a mixed picture around Claritev, with bullish analysts highlighting growth potential and margin strength, while more cautious voices focus on balance sheet risk and how much optimism is already reflected in the share price.Aggiornamento della narrazione • Dec 25
CTEV: Mid Single Digit Revenue Recovery Will Support Best In Class Margins
Analysts have raised their price target on Claritev from 55 dollars to 80 dollars, citing increased confidence that the company can reaccelerate to mid single digit revenue growth by 2026 while sustaining best in class margins. Analyst Commentary Recent research notes highlight a more constructive stance on Claritev's long term prospects, with the latest upgrade reflecting greater confidence in management's roadmap to restore sustainable growth while preserving strong profitability.Aggiornamento della narrazione • Dec 11
CTEV: Best-In-Class Margins Will Support Return To Mid-Single-Digit Expansion
Claritev's analyst price target has been raised to $74 from $55, as analysts cite growing confidence that the company can return to mid single digit revenue growth by 2026 while sustaining best in class margins. Analyst Commentary Bullish Takeaways Bullish analysts view the higher $74 target as reflecting renewed confidence in Claritev's ability to reaccelerate revenue growth while preserving margin discipline.Aggiornamento della narrazione • Nov 27
CTEV: Upgraded Buy Rating Will Drive Growth Momentum and Margin Strength
Analysts have raised Claritev’s price target from $80 to $85, reflecting renewed confidence in the company’s accelerating growth and its ability to maintain strong margins. Analyst Commentary Analyst sentiment around Claritev continues to evolve as the company demonstrates a strong execution track record and new growth initiatives.Aggiornamento della narrazione • Nov 06
CTEV: Upgraded Buy Rating Will Drive Renewed Momentum Through 2026
Narrative Update on Claritev Analysts have raised Claritev's price target from $55 to $74, citing increased confidence in the company's plan to accelerate growth and maintain industry-leading margins. Analyst Commentary Following the recent upgrade and price target revision, analysts have shared a range of insights on Claritev’s prospects and execution trajectory.Articolo di analisi • Nov 01
Improved Revenues Required Before Claritev Corporation (NYSE:CTEV) Stock's 35% Jump Looks Justified
Claritev Corporation ( NYSE:CTEV ) shares have continued their recent momentum with a 35% gain in the last month alone...Aggiornamento della narrazione • Oct 23
Analysts Boost Claritev Valuation Amid Growth Optimism and Strategic Developments
Analysts have raised Claritev's fair value estimate from $70.50 to $80.00. They cite growing confidence in the company's accelerated revenue growth outlook and sustained margins following the recent price target upgrade.Articolo di analisi • Sep 09
Claritev Corporation's (NYSE:CTEV) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Despite an already strong run, Claritev Corporation ( NYSE:CTEV ) shares have been powering on, with a gain of 27% in...Aggiornamento della narrazione • Aug 08
Digital Transformation And AI Adoption Will Drive Global Healthcare Expansion
Claritev’s future P/E has increased markedly while net profit margin has declined, indicating higher valuation despite weaker profitability, yet the consensus price target remains unchanged at $49.50. What's in the News Claritev updated full-year 2025 revenue guidance to flat to +2% versus 2024.Articolo di analisi • Jul 30
Claritev (NYSE:CTEV) Use Of Debt Could Be Considered Risky
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Jul 09
Claritev Corporation's (NYSE:CTEV) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Claritev Corporation ( NYSE:CTEV ) shares have continued their recent momentum with a 25% gain in the last month alone...Nuova narrazione • May 30
AI And Global Partnerships Will Reshape Personalized Medicine
AI-powered analytics, digital transformation, and global expansions position Claritev to monetize higher-value healthcare solutions and tap into growing, aging populations.Articolo di analisi • May 15
Claritev Corporation (NYSE:CTEV) Shares Fly 30% But Investors Aren't Buying For Growth
Claritev Corporation ( NYSE:CTEV ) shareholders would be excited to see that the share price has had a great month...Articolo di analisi • Mar 20
Little Excitement Around Claritev Corporation's (NYSE:CTEV) Revenues As Shares Take 28% Pounding
Claritev Corporation ( NYSE:CTEV ) shares have retraced a considerable 28% in the last month, reversing a fair amount...Articolo di analisi • Feb 03
There's No Escaping MultiPlan Corporation's (NYSE:MPLN) Muted Revenues Despite A 29% Share Price Rise
MultiPlan Corporation ( NYSE:MPLN ) shares have continued their recent momentum with a 29% gain in the last month...Articolo di analisi • Dec 20
MultiPlan Corporation (NYSE:MPLN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Those holding MultiPlan Corporation ( NYSE:MPLN ) shares would be relieved that the share price has rebounded 28% in...Articolo di analisi • Dec 13
Here's Why MultiPlan (NYSE:MPLN) Is Weighed Down By Its Debt Load
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Oct 20
MultiPlan Corporation (NYSE:MPLN) Shares Fly 55% But Investors Aren't Buying For Growth
MultiPlan Corporation ( NYSE:MPLN ) shareholders are no doubt pleased to see that the share price has bounced 55% in...Articolo di analisi • Aug 18
MultiPlan Corporation (NYSE:MPLN) Not Doing Enough For Some Investors As Its Shares Slump 40%
To the annoyance of some shareholders, MultiPlan Corporation ( NYSE:MPLN ) shares are down a considerable 40% in the...Articolo di analisi • Jul 04
Little Excitement Around MultiPlan Corporation's (NYSE:MPLN) Revenues As Shares Take 46% Pounding
Unfortunately for some shareholders, the MultiPlan Corporation ( NYSE:MPLN ) share price has dived 46% in the last...Articolo di analisi • Jul 02
MultiPlan (NYSE:MPLN) Use Of Debt Could Be Considered Risky
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • May 09
MultiPlan Corporation (NYSE:MPLN) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the MultiPlan Corporation ( NYSE:MPLN ) share price has dived 29% in the last...Rendimenti per gli azionisti
| CTEV | US Healthcare Services | US Mercato | |
|---|---|---|---|
| 7D | -23.0% | 1.1% | -0.3% |
| 1Y | -26.2% | -38.1% | 26.7% |
Ritorno vs Industria: CTEV ha superato il US Healthcare Services che ha restituito -38.1 % nell'ultimo anno.
Rendimento vs Mercato: CTEV ha avuto una performance inferiore al mercato US che ha registrato un rendimento 26.7 % nell'ultimo anno.
Volatilità dei prezzi
| CTEV volatility | |
|---|---|
| CTEV Average Weekly Movement | 23.5% |
| Healthcare Services Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di CTEV è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale di CTEV è aumentata da 17% a 24% nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1980 | 3,000 | Travis Dalton | www.claritev.com |
Claritev Corporation, insieme alle sue consociate, fornisce soluzioni di analisi dei dati e di gestione dei costi end-to-end, di pagamento e di integrità dei ricavi al settore sanitario negli Stati Uniti. L'azienda offre soluzioni di claims intelligence, tra cui prezzi basati su riferimenti, servizi di negoziazione, servizi di fatturazione a sorpresa e Vistara; soluzioni di rete, come reti primarie, reti complementari e servizi di costruzione e gestione della rete; e soluzioni di pagamento e integrità delle entrate, tra cui negoziazione clinica, integrità pre-pagamento, integrità post-pagamento e servizi di integrità delle entrate. Fornisce inoltre soluzioni di dati e analisi, tra cui PlanOptix, CompleteVue, BenInsights, punteggi di rischio e servizi supplementari per i vettori.
Claritev Corporation Riepilogo dei fondamenti
| CTEV statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$276.17m |
| Utili (TTM) | -US$286.52m |
| Ricavi(TTM) | US$978.76m |
0.4x
Rapporto P/S-1.3x
Rapporto P/ECTEV è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| CTEV Conto economico (TTM) | |
|---|---|
| Ricavi | US$978.76m |
| Costo del fatturato | US$262.06m |
| Profitto lordo | US$716.71m |
| Altre spese | US$1.00b |
| Utili | -US$286.52m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -16.81 |
| Margine lordo | 73.23% |
| Margine di profitto netto | -29.27% |
| Rapporto debito/patrimonio netto | -2,012.5% |
Come si è comportato CTEV nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/20 15:08 |
| Prezzo dell'azione a fine giornata | 2026/05/20 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Claritev Corporation è coperta da 8 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Steven Valiquette | Barclays |
| Glen Santangelo | Barclays |
| Andrew D'Silva | B. Riley Securities, Inc. |